Prognostic Value of Metabolic Tumor Volume Estimated by 18 F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Hong, J. | - |
dc.contributor.author | Kim, S.G. | - |
dc.contributor.author | Hwang, K.H. | - |
dc.contributor.author | Kim, M. | - |
dc.contributor.author | Ahn, H.K. | - |
dc.contributor.author | Sym, S.J. | - |
dc.contributor.author | Park, J. | - |
dc.contributor.author | Cho, E.K. | - |
dc.contributor.author | Shin, D.B. | - |
dc.contributor.author | Lee, J.H. | - |
dc.date.available | 2020-02-28T18:45:23Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2014-09 | - |
dc.identifier.issn | 1869-3474 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/13036 | - |
dc.description.abstract | Purpose: The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-containing immunochemotherapy. Methods: Patients with newly diagnosed DLBCL who underwent pre-treatment torso FDG-PET/CT scan taken within 10 days before treatment were included. MTV was defined as the volume of hypermetabolic tissue with a standardized uptake value (SUV) greater than a threshold value of 2.5 and calculated using volume viewer software. Association of MTV with patient characteristics and survival were compared. Results: A total of 96 patients were evaluated. During a median follow-up period of 27.8 months, 3-year event-free survival (EFS) and overall survival was 69.5 % and 72.9 %, respectively. The Ann Arbor staging showed a limitation of prognosis because there was no difference of EFS between patients with Ann Arbor stage II and those with stage III. On the contrary, among patients with Ann Arbor stage II or III disease (n = 53), the higher MTV group showed significantly inferior EFS compared with the lower MTV group. Conclusions: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease. © 2014 Korean Society of Nuclear Medicine. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Springer Verlag | - |
dc.relation.isPartOf | Nuclear Medicine and Molecular Imaging | - |
dc.title | Prognostic Value of Metabolic Tumor Volume Estimated by 18 F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.1007/s13139-014-0280-6 | - |
dc.identifier.bibliographicCitation | Nuclear Medicine and Molecular Imaging, v.48, no.3, pp.187 - 195 | - |
dc.identifier.kciid | ART001910895 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84906736913 | - |
dc.citation.endPage | 195 | - |
dc.citation.startPage | 187 | - |
dc.citation.title | Nuclear Medicine and Molecular Imaging | - |
dc.citation.volume | 48 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Kim, J. | - |
dc.contributor.affiliatedAuthor | Hong, J. | - |
dc.contributor.affiliatedAuthor | Kim, S.G. | - |
dc.contributor.affiliatedAuthor | Hwang, K.H. | - |
dc.contributor.affiliatedAuthor | Kim, M. | - |
dc.contributor.affiliatedAuthor | Ahn, H.K. | - |
dc.contributor.affiliatedAuthor | Sym, S.J. | - |
dc.contributor.affiliatedAuthor | Park, J. | - |
dc.contributor.affiliatedAuthor | Cho, E.K. | - |
dc.contributor.affiliatedAuthor | Shin, D.B. | - |
dc.contributor.affiliatedAuthor | Lee, J.H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Diffuse large cell lymphoma | - |
dc.subject.keywordAuthor | Metabolic tumor volume | - |
dc.subject.keywordAuthor | Positron-emission tomography | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Tumor burden | - |
dc.subject.keywordPlus | fluorodeoxyglucose f 18 | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cancer mortality | - |
dc.subject.keywordPlus | cancer prognosis | - |
dc.subject.keywordPlus | cancer staging | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | computer assisted emission tomography | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | image analysis | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | metabolic parameters | - |
dc.subject.keywordPlus | metabolic tumor volume | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | pancreatic neuroendocrine tumor | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | radiological parameters | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | standardized uptake value | - |
dc.subject.keywordPlus | total lesion glycolysis | - |
dc.subject.keywordPlus | tumor volume | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.